Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York

Jyotirmayee Lenka; Mamta S. Chhabria; Naman Sharma; Bryan E-Xin Tan; Leela Krishna Teja Boppana; Sharini Venugopal; Damanpaul S. Sondhi

doi:10.1101/2020.06.18.20135046

Abstract

Background There are limited reports describing critically ill COVID-19 patients in New York.

Methods We conducted a retrospective analysis of 32 adult critically ill patients admitted to a tertiary community hospital in upstate NY, between March 14th and April 12th, 2020. We collected demographic, laboratory, ventilator, and treatment data, which were analyzed and clinical outcomes tabulated.

Results 32 patients admitted to the ICU were included, with mean (±SD) follow-up duration 21 ± 7 days. Mean (±SD) age was 62.2 ± 11.2 years, and 62.5% were men. 27 (84.4%) of patients had one or more medical co-morbidities and 50% of the patients were current or former smokers. The mean (±SD) duration of symptoms was 6.6 (±4.4) days before presentation, with cough (81.3%), dyspnea (68.7%), and fever (65.6%) being most common. 23 (71.9%) patients received invasive mechanical ventilation. 5 (15.6%) had died, 11 (34.4%) had been discharged home, and 16 (50%) remained hospitalized, 8 (25%) of which were still in ICU. Mean (±SD) length of ICU stay was 10.2 (±7.7) days, and mean (±SD) length of hospital stay was 14.8 (±7.7) days.

Conclusion Majority of patients were of older age and with medical co-morbidities. With adequate resource utilization, mortality of critically ill COVID-19 patients may not be as high as previously suggested.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding source

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Rochester Regional Health (RRH) Institutional Review Board approved our case series (IRB:1982A). Informed consent was waived and researchers analyzed only de-identified data.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Conflict of interest statements: None of the authors (JL, MSC, NS, BEXT, LKTB, SV, and DSS) have any conflicts of interest to declare.
Funding Source: none

Data Availability

We collected demographic, clinical, laboratory, radiological, ventilator and treatment data by manual review of electronic medical records (EPIC EMR) of patients admitted to our medical intensive care unit. The data was then de-identified, prior to analysis.